ECSP067039A - Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5 - Google Patents

Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5

Info

Publication number
ECSP067039A
ECSP067039A EC2006007039A ECSP067039A ECSP067039A EC SP067039 A ECSP067039 A EC SP067039A EC 2006007039 A EC2006007039 A EC 2006007039A EC SP067039 A ECSP067039 A EC SP067039A EC SP067039 A ECSP067039 A EC SP067039A
Authority
EC
Ecuador
Prior art keywords
etinil
pirazoles
piridin
mglu5
imidazoles
Prior art date
Application number
EC2006007039A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Phillip Porter
Eric Vieira
Paul Spurr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/005881 external-priority patent/WO2004108701A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP067039A publication Critical patent/ECSP067039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a derivados de diazol de la fórmula general en la que A, E, R1, R2 y R3 tienen los significados definidos en las reivindicaciones y en la descripción, a su utilización para la fabricación de medicamentos destinados al tratamiento de enfermedades y a procesos para la obtención de los mismos.
EC2006007039A 2004-06-01 2006-11-28 Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5 ECSP067039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2004/005881 WO2004108701A1 (en) 2003-06-05 2004-06-01 Imidazole derivatives as glutmate receptor antagonists
EP04021216 2004-09-07

Publications (1)

Publication Number Publication Date
ECSP067039A true ECSP067039A (es) 2006-12-29

Family

ID=35758209

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007039A ECSP067039A (es) 2004-06-01 2006-11-28 Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5

Country Status (20)

Country Link
US (2) US20060030559A1 (es)
JP (1) JP4690395B2 (es)
KR (2) KR101057032B1 (es)
AR (1) AR054072A1 (es)
AU (1) AU2005250101B2 (es)
BR (1) BRPI0511678A (es)
CA (1) CA2568725C (es)
CR (1) CR8742A (es)
CY (1) CY1108232T1 (es)
DK (1) DK1756086T3 (es)
EA (1) EA011722B1 (es)
EC (1) ECSP067039A (es)
ES (1) ES2307182T3 (es)
HR (1) HRP20080363T3 (es)
IL (1) IL179524A (es)
MA (1) MA28602B1 (es)
NZ (1) NZ551253A (es)
PT (1) PT1756086E (es)
SI (1) SI1756086T1 (es)
TW (1) TWI297683B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329703B2 (en) * 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3400220B1 (en) * 2016-01-05 2021-03-24 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
EP3436009B1 (en) * 2016-03-30 2024-03-06 Sinntaxis AB Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages.
BR112022024760A2 (pt) 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa
BR112023001621A2 (pt) * 2020-07-30 2023-04-04 Noema Pharma Ag Métodos de tratamento de neuralgia trigeminal

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3033199A (en) * 1959-10-13 1962-05-08 Jacobs Clifford Roy Closure for protective device
US3045022A (en) 1960-04-07 1962-07-17 Reilly Tar & Chem Corp Process of preparing ethynylpyridines
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) * 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4508560A (en) 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
US4711962A (en) * 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
SG52709A1 (en) 1989-06-30 1998-09-28 Du Pont Substituted imidazoles
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
CA2297732C (en) 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
IL136553A0 (en) 2000-06-05 2001-06-14 Compugen Ltd SPLICE VARIANT OF mGluR
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
WO2002046166A1 (en) 2000-12-04 2002-06-13 F. Hoffmann-La Roche Ag Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
EP1238586A1 (en) 2001-03-09 2002-09-11 Basf Aktiengesellschaft Herbicidal 2-alkynyl-pyri(mi)dines
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
JP4303109B2 (ja) 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003053922A2 (en) 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
JP2006513996A (ja) 2002-10-24 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
ITMI20030151A1 (it) 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
DE102004032567A1 (de) 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
SI1756086T1 (sl) 2008-08-31
EA011722B1 (ru) 2009-04-28
KR20070021231A (ko) 2007-02-22
US8293916B2 (en) 2012-10-23
JP2008500979A (ja) 2008-01-17
ES2307182T3 (es) 2008-11-16
KR100907108B1 (ko) 2009-07-09
CY1108232T1 (el) 2014-02-12
HK1105972A1 (zh) 2008-02-29
TWI297683B (en) 2008-06-11
AR054072A1 (es) 2007-06-06
US20100048569A1 (en) 2010-02-25
PT1756086E (pt) 2008-08-08
JP4690395B2 (ja) 2011-06-01
EA200602154A1 (ru) 2007-06-29
TW200609222A (en) 2006-03-16
AU2005250101A1 (en) 2005-12-15
NZ551253A (en) 2010-07-30
CA2568725A1 (en) 2005-12-15
KR101057032B1 (ko) 2011-08-16
CR8742A (es) 2007-08-28
AU2005250101B2 (en) 2011-08-25
HRP20080363T3 (hr) 2008-09-30
IL179524A (en) 2012-04-30
US20060030559A1 (en) 2006-02-09
KR20080089523A (ko) 2008-10-06
BRPI0511678A (pt) 2008-01-08
IL179524A0 (en) 2007-05-15
DK1756086T3 (da) 2008-08-04
MA28602B1 (fr) 2007-05-02
CA2568725C (en) 2012-11-27

Similar Documents

Publication Publication Date Title
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CR10233A (es) Piridin-4-ilmetilamidas
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
CR11429A (es) Derivados bis-(sulfonilamino) en terapia 066
PA8647401A1 (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa,
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
CO6541656A2 (es) 2-amino-5.5- difluor-5.6-dihidro-4h-oxazinas como inhibidores de bace1 y/o bace 2
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
UY32387A (es) Ciclopentanodionas herbicidamente activas, derivados, procesos para su preparación, composiciones que las comprenden y usos de las mismas
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
SV2011003855A (es) Heteroarilos sustituidos
UY32918A (es) Nuevos compuestos de 2-piridona
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
ECSP11011485A (es) Espiro-epóxidos como productos intermedios.